An interim analysis of AstraZeneca and partner Ionis Pharmaceuticals’ eplontersen showed the experimental drug met the main goals in a late-stage trial in patients with a rare, fatal disease, the Anglo-Swedish drugmaker said on Tuesday.
Pharmaceutical powerhouse AstraZeneca appears to have taken an interest in the company’s London-based partner Mereo BioPharma and may be considering a buyout, according to circulating speculations first reported by The Times UK.
The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.
Although a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe — Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca-Oxford — a number of companies are continuing to develop vaccines in hopes they can be used as booster shots.
GSK aims to get the company’s respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly watched late-stage study involving older adults.
AstraZeneca announced Wednesday that the results of the company’s TACKLE Phase III trial of Evusheld (tixagevimab and cilgavimab, formerly AZD7442) for the early outpatient treatment of mild-to-moderate COVID-19 have been published in The Lancet Respiratory Medicine. Results of the trial showed that Evusheld protected against progression to severe COVID-19 or death – from any cause – compared to placebo.
AstraZeneca and Daiichi Sankyo’s Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy, according to data presented on Sunday.
Although cancer screening and diagnosis was hit by the coronavirus pandemic, resulting advances in medical technology and greater diversity in clinical trials could help treatments in the future, an AstraZeneca executive said.